Prediction of Split Renal Function Improvement After Renal Artery Stenting by Blood Oxygen Level–Dependent Magnetic Resonance Imaging

Zhiyong Lin1,2†, Bihui Zhang1†, Letao Lin1,3,4†, Rui Wang2, Guochen Niu1, Ziguang Yan1, Yinhua Zou1, Xiaqiang Tong1, Jianxing Qiu2* and Min Yang1**

1 Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China, 2 Department of Radiology, Peking University First Hospital, Beijing, China, 3 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, 4 Minimally Invasive Interventional Division, Sun Yat-sen University Cancer Center, Guangzhou, China

Background: The discrepancy between the high technical success rate and the relatively low clinical response rate of renal artery stenting (RAS) raises the importance to identify atherosclerotic renal artery stenosis (ARAS) patients who are most likely to benefit from RAS. This study aimed to investigate the feasibility and accuracy of blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) in predicting split renal function (SRF) improvement after RAS in patients with ARAS.

Methods: Thirty patients with severe ARAS who were treated with RAS were enrolled. Baseline cortical and medullary $R_2^*$ values of each kidney were measured by BOLD-MRI, and each patient’s SRF was evaluated by nuclear renal dynamic imaging at baseline and 1-month follow-up.

Results: In total, 35 severe stenotic renal arteries of the 30 patients were analyzed. At 1-month follow-up, 34 kidneys (97.1%) of severe ARAS had acquired SRF. SRF improved in 12 kidneys of 10 patients. The cortical $R_2^*$ and medullary $R_2^*$ values in the SRF improvement kidneys were higher than those in the non-improvement kidneys ($P \leq 0.001$). The area under the curve of medullary $R_2^*$ was 0.879 (95% confidence interval [CI] 0.736–1.000). A medullary $R_2^*$ value $\geq 29.1 \text{s}^{-1}$ was noted to provide good sensitivity (0.833, 95% CI 0.552–0.970) and specificity (0.864, 95% CI 0.667–0.953) in predicting SRF improvement. Medullary $R_2^*$ value was the only independent predictor of SRF improvement in multivariable analysis ($P = 0.034$, OR 3.017, 95%CI 1.089–8.358).

Conclusion: This study showed that a BOLD-MRI medullary $R_2^*$ value $\geq 29.1 \text{s}^{-1}$ was an excellent predictor of SRF improvement in patients with severe ARAS who underwent renal artery stenting.

Keywords: atherosclerotic renal artery stenosis, renovascular stenting, renal artery stenting, blood oxygen level-dependent magnetic resonance imaging, prediction
INTRODUCTION

Atherosclerotic renal artery stenosis (ARAS) is the most common cause of secondary hypertension, with severe stenosis (>60%) occurring in 6.8% of elderly patients (1–3). Renal artery stenting (RAS) is the preferred treatment option. Still, recent randomized trials have reported that when RAS is combined with the best medical therapy, there is no benefit regarding blood pressure, renal function, cardiovascular events, or mortality compared to medical treatment alone (4–6). However, these trials had significant design flaws, including variability in inclusion and exclusion criteria, inconsistent definitions of improvement, and differing endpoints, making the selection of patients for renal artery stenting controversial (7–9). For this reason, determining a biomarker to help predict RAS outcomes and identify patients who would best respond to RAS is of great clinical significance (8, 9).

Currently, several biomarkers are used to select patients likely to benefit from RAS, including resistance index (RI), translesional pressure gradient, renal artery fractional flow reserve, and brain natriuretic peptide (10). However, these methods are either invasive or not sufficiently accurate to be applied widely. Blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) is a non-invasive imaging technique that can assess the kidney’s regional oxygenation (11). It uses endogenous deoxygenated hemoglobin as a contrast agent and detects magnetic field disturbances caused by changes of oxygenated hemoglobin within the kidney tissue (11). The R2* score is the magnetic rate of relaxation that correlates positively with deoxyhemoglobin levels and can evaluate the severity of ischemia caused by ARAS (12, 13).

The present study evaluated the feasibility and accuracy of using BOLD-MRI to identify severe ARAS patients who might benefit from RAS in split renal function (SRF).

MATERIALS AND METHODS

Patients

This prospective study enrolled patients with severe ARAS consecutively from May 2018 to November 2018 and was approved by the Human Investigations Committee of Peking University First Hospital (2018263). The inclusion criteria were as follows: (1) patient age was ≥40 years; (2) the degree of stenosis on the treatment side of the renal artery was ≥70% (including occlusion), and there was no definite stenosis in the branches of the renal artery; (3) Renal artery stenosis was caused by atherosclerosis, which included (a) a minimum of 1 atherosclerosis risk factor (age ≥40, diabetes, hyperlipidemia, obesity, or long-term smoking) and (b) a minimum of 2 imaging features of atherosclerosis (the lesion involved the ostium or proximal segment of the renal artery, eccentric stenosis or occlusion, irregular plaque, calcification, and signs of atherosclerosis in other abdominal vessels); (4) clinical symptoms related to renal artery stenosis were present, including hypertension (blood pressure >140/90 mmHg), impaired renal function (taking renal dynamic imaging as the reference standard, unilateral glomerular filtration rate (GFR) <34 ml/min), or acute pulmonary edema and unstable angina pectoris; and (5) patients signed informed consent. Exclusion criteria mainly included the following: Renal artery stenosis caused by non-atherosclerotic factors, such as Takayasu arteritis, fibromuscular dysplasia, congenital arterial malformation, restenosis after renal artery intervention, or graft RAS; severe renal dysfunction [serum creatinine >264 μmol/L (3.0 mg/dl)]; and atrophied kidney (length <7 cm). The complete inclusion and exclusion criteria are shown in the appendix. SRF was evaluated with radionuclide renal dynamic imaging and the GFRs of both kidneys were obtained at baseline and 1-month follow-up.

Endovascular Procedures

Patients were treated by experienced vascular specialists in a catheter lab. Local anesthesia was administered and supplemented with intravenous sedation when needed. At first, a renal artery digital subtraction angiography was performed, and the operator determined the degree of stenosis based on the angiography images. In terms of diameter stenosis, less than 50% was considered mild, 50–70% moderate, 70–99% severe, and 100% occlusion. For the patients with severe stenoses and occlusions, endovascular treatments were performed. A 7F short sheath was exchanged for artery access, a 7F guiding catheter was used to engage the ostium of the stenotic renal artery, and a 0.014-inch guidewire was manipulated to cross the stenotic lesion. A rapid exchange balloon, 3–5 mm in diameter, was advanced along the guidewire to predilate the lesion. After predilation, a balloon-expandable stent was induced through the guiding catheter and deployed at the stenotic segment. The length and diameter of the balloons and stents were chosen at the discretion of the operator. Completion angiography was performed to confirm procedural success. Technical success was defined as a <30% residual stenosis at the completion angiography.

Antiplatelet and Antihypertensive Protocol

Before the procedure, all patients underwent dual antiplatelet therapy (aspirin 100 mg/day and clopidogrel 75 mg/day) for at least 7 days or took a loading dose (aspirin 300 mg and clopidogrel 300 mg) 6 h before the procedure. During the procedure, heparin (3000 IU) was administered for anticoagulation after the insertion of a guiding catheter. All patients were prescribed dual antiplatelet therapy (aspirin 100 mg/day and clopidogrel 75 mg/day) for at least 3 months after the procedure and were converted to a single agent after that. Statin was prescribed for patients with dyslipidemia. Antihypertensive drugs were kept unchanged at baseline and after the endovascular treatment.

Magnetic Resonance Imaging Scan Protocol

All BOLD-MRI examinations were performed with a MAGNETOM Aera 1.5T MR scanner (Siemens Healthcare GmbH, Erlangen, Germany) using an 18-channel body
coil combined with a 32-channel spine coil. The BOLD-MRI examination was a plain scan without the use of contrast agents. A coronal position protocol of multiple-echo spoiled gradient recalled echo through the center of both kidneys was prescribed. The parameters were as follows: repetition time, 130 msec; 5 echoes (echo times: 9.43, 14.29, 19.05, 23.81, and 28.30 msec); flip angle, 90°; slices, 4; section thickness, 6 mm; slice gap, 1.8 mm; imaging matrix, 256 × 192; and field of view, 380 mm × 297 mm. The scanning sequence automatically calculated and produced the T2*-weighted mapping images.

Magnetic Resonance Imaging Quality Evaluation and Data Analysis

Two radiologists independently assessed the image quality of the BOLD-MRI in terms of image clarity, artifacts, and geometric distortion. Image quality was rated according to a 5-point Likert-type scale (1, non-diagnostic; 2, poor; 3, moderate; 4, good; and 5, excellent).

Analysis of BOLD-MRI data from coronal position images was performed by drawing a parenchymal region of interest (ROI) on the sections through each kidney’s mid pole hilar region on the T2*-weighted mapping images. Four ROIs were traced: One ROI of cortex was calculated after manual segmentation of the cortex while paying attention excluding the renal medulla, collecting system, incidental cysts, and hilar structures; three ROIs of the medulla were placed in circular areas on the upper, middle, and lower medulla of the kidney, with a diameter of about 3 mm (Figure 1).

After being trained in the standard unified measurement process, two radiologists measured the T2* values of the BOLD-MRI images separately in a blinded fashion. Any discrepancies were resolved in a consensus reading. The final T2* values were the average of the data measured by the two radiologists.

One T2* value was obtained for the cortex of each kidney. Three T2* values of ROIs were obtained for the medulla, and the average was calculated. Finally, to evaluate the degree of hypoxia in the kidney tissue, these values were converted into R2* values according to the following formula: R2* = 1/T2*.

Follow-Up and Definitions

Follow-up visits were scheduled at 1-month after discharge at the outpatient department. During the follow-up appointment, symptom inquiry, physical examination, renal artery duplex ultrasound scanning and nuclear renal dynamic imaging were conducted. The renal artery ultrasound measurements included peak systolic velocity (PSV) and RI. In the nuclear renal dynamic imaging scan, a bolus of 99mTc-DTPA (Technetium-99m diethylene triamine penta-acetic acid) was given through an antecubital vein. For renal blood flow evaluation, serial dynamic images are acquired every 2 s for a minute. To evaluate renal parenchymal function, a series of images are obtained after 1 min of the renal perfusion phase. Images are acquired at 60 s intervals for a period of 20 min.

Loss of patency was defined as ≥50% restenosis or stent thrombosis based on duplex ultrasound scanning. Change of GFR was defined as the difference between the GFR taken at the 1-month follow-up and the baseline. A modified definition of SRF...
Improvement was the change of GFR was ≥15% of the baseline GFR of the affected kidney and the absolute improvement was at least 5 ml/min.

Statistical Analysis
Statistical analysis was performed using SPSS software (version 20.0, IBM Corp., Armonk, NY, United States). The normally distributed continuous data are shown as mean ± standard deviation, continuous data without normal distribution are shown as the median and interquartile, and categorical data are shown as numbers and percentages. The normally distributed paired continuous variables were compared by 2-sided Student’s t-tests, and the non-normally distributed paired continuous variables were compared by the Wilcoxon signed-rank test. Mean values of independent variables were compared by an independent samples t-test when the homogeneity of variance was present and using Welch’s t-test when the variance homogeneity was absent. Categorical variables were compared using the 2-sided likelihood ratio chi-square test or Fisher exact test.

Pearson correlation coefficient was used to evaluate the correlation between the two groups of data with normal distribution, and Spearman correlation coefficient was used to evaluate the correlation between the two groups of data without normal distribution. Furthermore, 0.4 ≤ |r| < 0.7 was considered a moderate correlation, 0.7 ≤ |r| < 0.9 a high correlation, and |r| ≥ 0.9 a very high correlation.

The kappa value was used to analyze image quality consistency through a grade score, and the intraclass correlation coefficient (ICC) was used to evaluate the consistency of data measurement. The consistency was reported as poor when ICC < 0.4, good when 0.4 ≤ ICC ≤ 0.75, and very good when ICC > 0.75.

Receiver operating characteristic (ROC) curve analysis was performed to evaluate baseline cortical and medullary R2* performance across the patients analyzed. The area under the curve (AUC) was used to assess the overall accuracy. Youden’s index and clinical relevance would be considered when selecting the optimum cut-off point. Univariate and multivariate logistic regression were used to analyze the risk factors of the improvement of SRF after RAS. Characteristics of patients and lesions, and BOLD parameters were placed in the analysis model.

Outcomes were reported as the hazard ratio and 95% confidence interval (CI). A P-value of less than 0.005 was considered statistically significant.

RESULTS

Patient and Procedural Characteristics
A total of 30 patients with ARAS were included in this study. The flowchart of patients is shown in Figure 2. Demographic and baseline information is shown in Table 1. The average age was 63.97 ± 9.44 years, and 73.3% of patients were male. All patients suffered from high blood pressure, and the median number of antihypertensive agents was 2.

Bilateral renal artery lesions were found in 9 patients, 4 of whom had unilateral renal artery occlusion that could not be crossed due to 70% stenosis confirmed by angiography in three patients with unilateral renal artery stenosis and unsuccessful guidewire crossing in four patients with bilateral renal artery lesions. The missing patient had 1-month follow-up, but didn’t complete the nuclear renal dynamic imaging.

![Screen failure (n=3, N=7) ![Enrolled (n=30, N=35) ![Follow-up completed (n=29, N=34) ![SRF improvement (n=10, N=12) ![SRF non-improvement (n=19, N=22) ![Flow chart of patients and lesions. n stands for number of renal artery lesions.](image)

**Figure 2** Flow chart of patients and lesions. n stands for number of renal artery lesions. A total of 30 patients with ARAS were included in this study. Demographic and baseline information is shown in Table 1. The average age was 63.97 ± 9.44 years, and 73.3% of patients were male. All patients suffered from high blood pressure, and the median number of antihypertensive agents was 2.

![Table 1](image)

**Table 1** Patient characteristics (n = 30).

| Characteristics               | N = 30 |
|-------------------------------|--------|
| Age, years                    | 63.97 ± 9.44 |
| Male, n (%)                   | 22 (73.30) |
| BMI (kg/m²)                   | 25.00 ± 2.71 |
| Diabetes, n (%)               | 8 (26.70) |
| Dyslipidemia, n (%)           | 17 (56.70) |
| Cerebrovascular disease, n (%)| 6 (20.00) |
| Coronary heart disease, n (%) | 12 (40.00) |
| Peripheral artery disease, n (%)| 2 (6.70) |
| Smoking, n (%)                | 14 (46.7) |
| Hypertension, n (%)           | 30 (100.00) |
| Duration of hypertension, years| 4 (1.00, 10.00) |
| Systolic blood pressure (mmHg)| 160.77 ± 20.20 |
| Diastolic blood pressure (mmHg)| 87.70 ± 11.56 |
| Kinds of antihypertensive agents | 2 (1.00, 3.00) |
| Use of ACEI/ARB, n (%)        | 12 (40.00) |
| Use of diuretics, n (%)       | 7 (23.30) |
| Use of β-Blockers             | 12 (40.00) |
| Renal insufficiency, n (%)    | 11 (36.67) |
| Serum creatinine (µmol/L)     | 125.75 (97.06, 147.94) |
| eGFR (mL/min/1.73m²)          | 52.64 ± 18.72 |

BMI, Body Mass Index; ACEI, Angiotensin Converting-Enzyme Inhibitor; ARB, Angiotensin II Receptor Blocker; eGFR, estimated Glomerular Filtration Rate; Renal insufficiency was defined as serum creatinine > 133 µ mol/L.
not be recanalized successfully, and unilateral ARAS was found in 21 patients who all undertook RAS successfully. Overall, 35 renal arteries were treated by stents (31 PALMAZ BLUE, Cordis, FL, United States; 1 Herculink Elite, Abbott Vascular, CA, United States; 1 Acculink, Abbott Vascular, CA, United States and 2 Express Vascular, Boston Scientific, MA, United States).

Quality and Consistency of Blood Oxygen Level-Dependent Imaging
The quality of the acquired images met the need for diagnosis regarding resolution, artifacts, and deformation. The kappa value of the image quality was 0.816.

A total of 35 kidneys with severe ARAS were included for evaluation of cortical and medullary T2* at baseline. The ICC was 0.921 (95% CI 0.887–0.945) for cortical T2* and 0.818 (95% CI 0.74–0.871) for medullary T2*, indicating that the two radiologists noted a high consistency in estimating both cortical and medullary T2*.

Oxygenation Level of Kidneys With Severe Atherosclerotic Renal Artery Stenosis
The oxygenation level of affected kidneys was compared with the contralateral kidneys in the 21 patients with severe unilateral ARAS. The cortical and medullary T2* values of the affected kidneys were significantly lower than those of the contralateral kidneys (P = 0.007 and P < 0.001, respectively). Accordingly, the R2* (1/T2*) values were higher in the affected side than in the contralateral side (P = 0.003 and P < 0.001, respectively). Details are shown in Table 2.

One-Month Outcomes of Endovascular Treatment
All patients with severe ARAS had a 1-month follow-up. The parameters of global renal function and blood pressure at both the baseline and follow-up are given in Table 3. The average systolic blood pressure decreased from 160.77 ± 20.20 mmHg at baseline to 132.80 ± 10.56 mmHg at the 1-month follow-up (P < 0.001). The average diastolic blood pressure decreased from 87.70 ± 11.56 mmHg to 78.27 ± 9.00 mmHg (P < 0.001). Parameters regarding global renal function did not change.

For the 35 renal arteries treated and evaluated at follow-up, no loss of patency was found by ultrasound (Table 4). The velocity of renal artery flow decreased significantly (0.98 ± 0.34 m/s vs. 2.96 ± 1.45 m/s, P < 0.001). One patient did not complete the nuclear renal dynamic imaging at the 1-month follow-up. SRF improvement occurred in 35.3% (12/34) of the stented kidneys in 34.5% (10/29) of the patients. The average split GFR increased significantly (19.56 ± 11.86 ml/min vs. 17.16 ± 11.69 ml/min, P = 0.013).

The Correlation of Oxygenation Level at Baseline and Change of Glomerular Filtration Rate
Correlations between the baseline oxygenation level of the renal cortex and medulla, and the 1-month change of ipsilateral GFR were analyzed in the 34 kidneys treated by RAS. Pearson correlation analysis showed that there was a moderate positive correlation between the GFR change and baseline cortical R2* value (r = 0.674; P < 0.001; Figure 3A).

---

**TABLE 2** | BOLD-MRI comparison of the affected kidney and contralateral kidney in patients with unilateral ARAS.

| The severely stenotic kidney (n = 21) | The contralateral kidney (n = 21) | P   |
|-------------------------------------|---------------------------------|-----|
| T2* (ms)                            | 78.12 ± 10.86                   | 85.16 ± 5.50 | 0.007 |
| R2* (ms)                            | 13.03 ± 1.78                    | 11.79 ± 0.74 | 0.003 |
| Medullary T2* (ms)                  | 38.37 ± 4.96                    | 44.16 ± 2.59 | <0.001 |
| R2* (ms)                            | 26.48 ± 3.38                    | 22.72 ± 1.35 | <0.001 |

BOLD-MRI, Blood Oxygen Level-Dependent Magnetic Resonance Imaging; ARAS, Atherosclerotic Renal Artery Stenosis.

**TABLE 3** | Comparison of global renal function and blood pressure at baseline and 1-month follow-up.

| Variables                        | At baseline (n = 30) | At 1-month follow up (n = 30) | P  |
|----------------------------------|----------------------|-------------------------------|----|
| Serum creatinine (µmol/L)        | 125.75 (97.06, 147.94) | 118.50 (97.43, 146.25) | 0.951 |
| eGFR (mL/min/1.73m²)             | 52.64 ± 18.72        | 53.39 ± 17.16                | 0.695 |
| Urine creatinine (mmol/L)        | 4.70 (3.85, 7.45)    | 7.05 (4.78, 12.40)           | 0.063 |
| Urine microalbumin (mg/L)        | 27.90 (3.91, 166.50) | 22.35 (6.23, 63.70)          | 0.370 |
| Systolic blood pressure (mmHg)   | 160.77 ± 20.20       | 132.80 ± 10.56               | <0.001 |
| Diastolic blood pressure (mmHg)  | 87.70 ± 11.56        | 78.27 ± 9.00                 | <0.001 |

eGFR, estimated Glomerular Filtration Rate.
and baseline medullary $R_2^*$ value ($r = 0.483; P = 0.004$; Figure 3B).

The baseline cortical $R_2^*$ and medullary $R_2^*$ in the SRF improvement group ($14.4 \pm 1.8 \text{ s}^{-1}$ and $29.5 \pm 2.6 \text{ s}^{-1}$, respectively) were higher ($P = 0.001$ and $P < 0.001$, respectively) than those in the non-improvement group ($12.4 \pm 1.3 \text{ s}^{-1}$ and $25.4 \pm 2.9 \text{ s}^{-1}$, respectively), indicating that baseline cortical $R_2^*$ and medullary $R_2^*$ values could be candidates for predicting SRF improvement. For patients with SRF improvement, the serum creatinine level and eGFR did not change significantly ($P = 0.321$ and $P = 0.228$).

The Correlation of Oxygenation Level at Baseline and Change of Blood Pressure
The correlations of BOLD-derived renal oxygenation level and evolution of blood pressure were analyzed in 25 patients treated by RAS unilaterally. The baseline medullary $R_2^*$ had no correlation with absolute systolic blood pressure (SBP) change ($r = 0.102$ and $P = 0.628$), relative SBP change ($r = 0.138$ and $P = 0.509$), absolute diastolic blood pressure (DBP) change ($r = 0.195$ and $P = 0.352$), and relative DBP change ($r = 0.265$ and $P = 0.200$). Similarly, no correlation was found between the baseline cortical $R_2^*$ and changes of blood pressure (absolute SBP $P = 0.289$; relative SBP $P = 0.308$; absolute DBP $P = 0.494$; relative DBP $P = 0.484$).

The Role of $R_2^*$ at Baseline in Predicting Split Renal Function Improvement
The ROC curves of cortical $R_2^*$ and medullary $R_2^*$ are shown in Figure 4. The AUC of medullary $R_2^*$ was 0.879 (95% CI 0.736–1.000), larger than that of cortical $R_2^*$ (0.822, 95% CI 0.655–0.989), indicating that medullary $R_2^*$ had higher accuracy and is a better predictor. The cut-off value of baseline medullary $R_2^*$ was 29.1 s$^{-1}$, the sensitivity was 0.833 (95% CI 0.552–0.970), and the specificity was 0.864 (95% CI 0.667–0.953). The absolute values of GFR change were higher in patients with medullary $R_2^* > 29.1 \text{ s}^{-1}$ than in patients with medullary $R_2^* \leq 29.1 \text{ s}^{-1}$ (5.769 ± 5.644 vs. 0.309 ± 3.945, respectively).
TABLE 5 | Univariable and Multivariable predictors of split renal function improvement after renal artery stenting.

| Predictors | Univariable analysis | Multivariable analysis |
|------------|----------------------|------------------------|
|            | p-value | OR    | 95% confidence interval | p-value | OR    | 95% confidence interval |
| Age        | 0.462    | 1.031 | 0.951 1.117          |         |       |                       |
| Male       | 0.881    | 1.133 | 0.219 5.864          |         |       |                       |
| Smoking    | 1.000    | 1.000 | 0.245 4.083          |         |       |                       |
| Duration of hypertension | 0.133 | 0.883 | 0.750 1.039          |         |       |                       |
| Diabetes   | 0.346    | 2.333 | 0.400 13.609         |         |       |                       |
| Dyslipidemia | 0.611 | 1.444 | 0.351 6.947          |         |       |                       |
| Stroke     | 0.881    | 0.882 | 0.171 4.565          |         |       |                       |
| Coronary artery disease | 0.966 | 0.969 | 0.232 4.042          |         |       |                       |
| Baseline GFR | 0.878 | 0.995 | 0.936 1.058          |         |       |                       |
| Degree of stenosis | 0.641 | 1.023 | 0.930 1.124          |         |       |                       |
| Baseline PSV | 0.217 | 1.402 | 0.820 2.396          | 0.549    | 0.798 | 0.381 1.671          |
| Baseline RI | 0.510    | 0.163 | 0.001 36.047         |         |       |                       |
| Baseline kidney length | 0.353 | 1.352 | 0.715 2.554          |         |       |                       |
| Cortical R2* | 0.006 | 2.419 | 1.290 4.539          |         |       |                       |
| Medullary R2* | 0.006 | 1.674 | 1.157 2.422          | 0.034    | 3.017 | 1.089 8.358          |

GFR, Glomerular Filtration Rate; PSV, Peak Systolic Velocity; RI, Resistance Index.

The related randomized trials may have been confined by the use of global renal function as the outcome assessment (4–6). Due to the compensation achieved by hyperfiltering of the contralateral kidney in unilateral severe ARAS patients, there may be no net decline detected in the global renal function (9, 15, 16). In the present study, nuclear dynamic imaging was used to assess the SRF improvement of the stented kidney. In the SRF improvement group, the global renal function evaluated by serum creatinine did not improve significantly, which supports the theory mentioned above (9). Blood pressure improvement is an important target for treating ARAS, and its predictors, including translesional pressure gradients, intravascular ultrasound, and angiography, have been previously investigated and compared (17). In the present study, the blood pressure improvement was not correlated with baseline cortical and medullary R2*.

The potential limitations of our study should be noted. First, SRF improvement was only evaluated at 1-month follow-up, and therefore long-term results remain unknown. The reason for the relatively short follow-up is that other comorbidities that ARAS patients have can adversely affect renal function. For this reason, it is difficult to determine whether RAS improves renal function in the long run. Second, the study was confined to a single center, and the bias associated with the sample size may limit the generalizability of the results. Third, the BOLD-derived oxygen levels cannot predict the outcomes of total GFR and blood pressure improvement, which limits the clinical impact.

CONCLUSION

Blood oxygen level-dependent magnetic resonance imaging is useful for identifying severe ARAS patients whose SRF could
benefit from RAS. We found medullary $R_2^* \geq 29.1 \text{s}^{-1}$ to have good sensitivity and specificity, making it an excellent predictor of SRF improvement after RAS.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Peking University First Hospital Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, et al. Prevalence of renovascular disease in the elderly: a population-based study. *J Vasc Surg. (2002) 36:443–51. doi: 10.1067/mva.2002.127351*

2. de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. *J Hypertens. (2009) 27:1333–40. doi: 10.1097/HIJ.0b013e328239b6f4*

3. Simeoni M, Borrelli S, Garofalo C, Fuiano G, Esposito C, Comi A, et al. Atherosclerotic-nephropathy: an updated narrative review. *J Nephrol. (2021) 34:125–36. doi: 10.1007/s40620-020-00733-0*

4. Bax I, Woottiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. *Ann Intern Med. (2009) 150:840–48; w150–841. doi: 10.7326/0003-4819-150-12-200906160-00119*

5. Wheately K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization versus medical therapy for renal-artery stenosis. *N Engl J Med. (2009) 361:1953–62. doi: 10.1056/NEJMoa0905568*

6. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Reid DM, et al. Stenting and medical therapy for atherosclerotic-artery-stenosis. *N Engl J Med. (2014) 370:13–22. doi: 10.1056/NEJMoa1310753*

7. Raman G, Adam GP, Halladay CW, Langberg VN, Azodo IA, Raynaud P, et al. Comparative effectiveness of management strategies for renal artery stenosis: an updated systematic review. *Ann Intern Med. (2016) 165:635–49. doi: 10.7326/m16–1053*

8. de Leeuw PW, Postma CT, Siering W, Kroon AA. Atherosclerotic renal artery stenosis: should we intervene earlier? *Curr Hypertens Rep. (2018) 20:35. doi: 10.1007/s11906-018-0829-3*

9. Prince M, Tafur JD, White CJ. When and how should we revascularize patients with atherosclerotic renal-artery stenosis? *JACC Cardiovasc Interv. (2019) 12:505–17. doi: 10.1016/j.jcin.2018.10.023*

10. Tafur JD, White CJ. Renal artery stenosis: when to revascularize in 2017. *Curr Probl Cardiol. (2017) 42:110–35. doi: 10.1016/j.cpcardiol.2017.01.004*

11. Textor SC, Glockner JF, Lerman LO, Misra S, McKusick MA, Riederer SJ, et al. The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. *J Am Soc Nephrol. (2008) 19:780–8. doi: 10.1681/asn.2007040420*

12. Saad A, Herrmann SM, Crane J, Glockner JF, McKusick MA, Misra S, et al. Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. *Circ Cardiovasc Interv. (2013) 6:428–35. doi: 10.1161/circinterventions.113.000219*

13. Manohar S, Hamadah A, Herrmann SM, Texier SC. Total renal artery occlusion: recovery of function after revascularization. *Am J Kidney Dis. (2018) 71:748–53. doi: 10.1053/j.ajkd.2017.11.014*

14. Gloviczki ML, Saad A, Texier SC. Blood oxygen level-dependent (BOLD) MRI analysis in atherosclerotic renal artery stenosis. *Curr Opin Nephrol Hypertens. (2013) 22:519–24. doi: 10.1097/MNH.0b013e3283640b02*

15. Batch-Adanore A, Azizi M, Froissart M, Raynaud A, Plouin P. Split renal function outcome after renal angioplasty in patients with unilateral renal artery stenosis. *J Am Soc Nephrol. (2001) 12:1235–41. doi: 10.1681/asn. v1261235*

16. Saeed A, Fortuna EN, Jensen G. Split renal function in patients with unilateral atherosclerotic renal artery stenosis-effect of renal angioplasty. *Clin Kidney J. (2017) 10:496–502. doi: 10.1093/ckj/sfx052*

17. Leeser MA, Varma J, Shapira A, Fakshah I, Raza ST, Elghoul Z, et al. Prediction of hypertension improvement after stenting of renal artery stenosis: comparative accuracy of translesional pressure gradients, intravascular ultrasound, and angiography. *J Am Coll Cardiol. (2009) 53:2363–71. doi: 10.1016/j.jacc.2009.03.031*

**AUTHOR CONTRIBUTIONS**

ZL, BZ, and LL contributed in implementing and writing. RW, GN, and ZY contributed in implementing and data analysis. YZ, XT, IQ, and MY contributed in supervising. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by National Key R&D Program of China (grant no. 2017YFC0109105), the Scientific Research Seed Fund of Peking University First Hospital (grant no. 2018SF023), Youth clinical research project of Peking University First Hospital (grant no. 2018CR16), and Interdisciplinary clinical research project of Peking University First Hospital (grant no. 2018CR33).